236 
Market Cap
Stock Chart
Circadian - 30 Day Poll
Recent BLOGS About Circadian Add New
Latest Company News
|
NASA ISS On-Orbit Status 15 May 2012
Space Ref (press release) - May 15, 2012 >>>Today 25 years ago (1987), the Soviet Union launched the super-heavy launch vehicle Energia at Baikonur, carrying demo mockup satellite Polus as payload.
|
|
NASA ISS On-Orbit Status 30 April 2012
Space Ref (press release) - Apr 30, 2012 All ISS systems continue to function nominally, except those noted previously or below. Underway: Week 1 of Increment 31 (three-person crew).
|
|
NASA ISS On-Orbit Status 26 April 2012
Space Ref (press release) - Apr 27, 2012 Upon wakeup, FE-3 Dan Burbank, FE-5 André Kuipers & FE-6 Don Pettit each completed another post-sleep session of the Reaction Self-Test (Psychomotor Vigilance Self-Test on the ISS) protocol, the 44th Dan, the 38th for André & Don.
|
|
Circadian Technologies Limited's Subsidiary Receives FDA Investigational New Drug Approval
Reuters Key Development - Oct 30, 2011 |
|
Circadian Technologies Limited's Subsidiary Submits Investigational New Drug Application
Reuters Key Development - Sep 29, 2011 |
|
Circadian Technologies Limited Announces VGX-100 Identified As Potential New Therapy For Dry Eye Disease
Reuters Key Development - Sep 13, 2011 |
|
Circadian Technologies Limited Declares No FY 2010/2011 Final Dividend
Reuters Key Development - Aug 23, 2011 |
|
Circadian Technologies Limited Launches ADR Program And Dual Quotation In USA
Reuters Key Development - Jun 14, 2011 |
Website
Videos related to Circadian
Company Profile
Cash reserves (at market value): Dec 2011 were approx. $18.5 million
estimated cash burn per year by CEO is $9M p.a.
Shares held by:
Institutions/Funds: ~ 32%
Retail investors: ~ 40%
Professional investors: ~ 28%
Possible events coming:
In February 2011, Circadian launched its first diagnostic product, a serum based test to detect VEGF-D as a marker for respiratory disease. The company is expecting to enter clinical trials with VGX-100 by 2011Q4. Circadian targets to have clinical proof of principal from Phase 2 studies with VGX-100 by mid 2014. Circadian is looking to enter into a partnership with VGX-100 in the next 1-2 years.
- click here for more possible events...
Overview:
Circadian has moved from being a biotechnology investor and incubator to a developer of angiogenesis-based therapeutics for cancer and other serious diseases. More specifically developing antibody therapies with an anti-angiogenic approach.
The portfolio covering key targets (Vascular Endothelial Growth Factors C and D) for the treatment of diseases associated with angiogenesis has been accumulated in Circadian’s unlisted subsidiary, Vegenics Limited. On August 14, 2008, Circadian announced that it had completed its acquisition of the Ludwig Institute for Cancer Research Ltd’s (LICR) and Licentia Limited’s (Licentia) combined 33% interest in Vegenics. This increased Circadian’s interest in Vegenics Limited from 67% to 100%.
Has licensing deals with the following comapnies:
- ImClone Systems Inc (recently acquired by Eli Lilly & Co.
- Healthscope Limited (ASX:HSP) developing cancer diagnostic test
People:
Of note the "Product Development Advisory Committee" has strong experience in international drug developmentand oncology.
– Errol Malta (Chair): ex Amgen
– George Morstyn: ex CMO Amgen
– Russell Howard: CEO Nasdaq listed Maxygen
– Ralph Smalling: ex Amgen Reg Affairs
– Richard Morgan: ex Glaxo-Wellcome
– Carlo Montagner: ex Aventis, Schering, Abraxis
Top 10 Sahreholders include institutional and professional investors:
- Packer and Co Limited 17.1
- Select Asset Management Ltd 8.1
- Ludwig Institute for Cancer Research 5.7
- Licentia Ltd 5.6
- Leon Serry 4.6
- HSBC Custody Nominees 2.7
- Chemical Trustee Limited 2.3
- Jagen Pty Ltd 2.2
- JFF Steven Pty Ltd 1.8
- Audivac Pty Ltd 1.7
Total 10 shareholders own 51.8%
Related comapnies or competition:
- Bionomics, see
http://www.bioinvest.com.au/company/Bionomics